희귀 바이오마커 시료 채취 및 안정화 시장 : 유형별(순환 유리 DNA, 순환 종양 세포, 엑소좀 소포), 제품별, 용도별 - 세계 기회 분석 및 산업 예측(2021-2031년)

The global rare biomarkers specimen collection and stabilization market was valued at $23,270.04 million in 2021, and is projected to reach $54,145.59 million by 2031, registering a CAGR of 8.7% from 2022 to 2031. Biomarker is a measurable indicator of some biological state or condition. It is usually used in the measurement and evaluation of blood, urine, and soft tissues. Biomarkers focus on monitoring vital parameters such as heart rate and accelerometer data. In rare biomarker specimen collection, the rare disease-causing microorganisms are identified by evaluating blood and other parts of body.These samples are stabilized by using isolation kits, reagents, and other equipment for further study. Molecular biomarkers, cellular biomarkers, and imaging biomarkers are the three different types of biomarkers.

However, a biomarker can lessen the burden of the clinical trial process by providing information about the safety and efficacy of treatments before the collection of definitive clinical data, which provides the opportunity for mid-course re-appraisal, and even interruption if the intervention being investigated is revealed as potentially harmful to participants.

The key factors that drive the growth of market are rise in prevalence of chronic & genetic diseases, increase in incidence of rare diseases such as cystic fibrosis, muscular dystrophy, & spina bifida; and rise in geriatric population. For instance, in May, 2022 Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) Comprehensive (EU) test. This single test kit, launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.

Moreover, increased R&D activities for the launch of approved novel drugs on rare diseases, favorable government reimbursement policies for rare biomarkers, surge in investment in the modern healthcare facility sector, and rise in demand for accurate chronic disease diagnosis are anticipated to fuel the market growth.

However, stringent government regulations and high cost associated with the development of rare biomarkers specimen and standardization hamper the market growth. Conversely, emerging healthcare market in developing countries, increase in applications of rare biomarker specimens in pharmacogenomics, and surge in the risk of pandemic & rare genetic diseases are expected to provide lucrative opportunity for the growth of market during the forecast period. 

The rare biomarkers specimen collection and stabilization market is segmented on the basis of type, product, application, and region. By type, the market is categorized into circulating cell free DNA, circulating tumor cells, and exosomes vesicles. By product, the market is classified into isolation kits & reagents, blood collection tubes, and systems. By application, the market is fragmented into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and other. By application, the oncology segment is further sub-classified into research and diagnostics.Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the rare biomarker's specimen collection and stabilization market share in 2021 and is anticipated to remain dominant during the forecast period. The rare biomarkers specimen collection and stabilization market is mainly driven by rise in prevalence of chronic & genetic diseases, increase in the healthcare expenditure, surge in number of approved rare biomarker isolation kits for both clinical and research use are anticipated to increase the usage of liquid biopsy and assisted reproductive technology space in the region which propels the growth of the market.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period. This is due to the presence of high unmet medical needs and constantly improving healthcare infrastructure to cure chronic disorders. In addition, rise in investment for exploring the utility of circulating tumor cells (CTCs) in diagnosis, prognosis, and treatment monitoring have provided lucrative growth opportunities to players, which is further expected contribute to the growth of the market.

The key players that operate in the rare biomarkers specimen collection and stabilization market are Agilent Technologies, Bio-Rad Laboratories inc., Charles River Laboratories Inc, F. Hoffman La Roche AG, Merck KGaA, Miltenyi Biotec, Perkin Elmer, Qiagen, Thermofisher Scientific Inc and Siemens AG.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rare biomarkers specimen collection and stabilization market analysis from 2021 to 2031 to identify the prevailing rare biomarkers specimen collection and stabilization market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the rare biomarkers specimen collection and stabilization market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global rare biomarkers specimen collection and stabilization market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

• Circulating Cell Free DNA (ccfDNA)
• Circulating Tumor Cells (CTCs)
• Exosomes Vesicles

By Product

• Isolation Kits and Reagent
• Blood Collection Tubes
• Systems

By Application

• Transcriptomics
• Pharmacogenomics
• Transplant Rejection
• Population Screening
• Others
• Oncology
  • Type
  • Research
  • Diagnostics
• Cardiovascular Diseases
• NIPT

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • Agilent Technologies Inc
  • F Hoffman La Roche
  • Merck Kgaa
  • Bio Rad Laboratories
  • Thermofischer Scientific Inc
  • Qiagen
  • Perkin Elmer
  • Charles River Laboratories International, Inc.
  • Siemens Healthineers
  • Eurofins Scientific, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Circulating Cell Free DNA (ccfDNA)
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Circulating Tumor Cells (CTCs)
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Exosomes Vesicles
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country

CHAPTER 5: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Isolation Kits and Reagent
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Blood Collection Tubes
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Systems
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country

CHAPTER 6: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Oncology
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
  • 6.2.4 Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
    • 6.2.4.1 Research Market size and forecast, by region
    • 6.2.4.2 Diagnostics Market size and forecast, by region
• 6.3 Cardiovascular Diseases
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
• 6.4 NIPT
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country
• 6.5 Transcriptomics
  • 6.5.1 Key market trends, growth factors and opportunities
  • 6.5.2 Market size and forecast, by region
  • 6.5.3 Market analysis by country
• 6.6 Pharmacogenomics
  • 6.6.1 Key market trends, growth factors and opportunities
  • 6.6.2 Market size and forecast, by region
  • 6.6.3 Market analysis by country
• 6.7 Transplant Rejection
  • 6.7.1 Key market trends, growth factors and opportunities
  • 6.7.2 Market size and forecast, by region
  • 6.7.3 Market analysis by country
• 6.8 Population Screening
  • 6.8.1 Key market trends, growth factors and opportunities
  • 6.8.2 Market size and forecast, by region
  • 6.8.3 Market analysis by country
• 6.9 Others
  • 6.9.1 Key market trends, growth factors and opportunities
  • 6.9.2 Market size and forecast, by region
  • 6.9.3 Market analysis by country

CHAPTER 7: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Type
  • 7.2.3 North America Market size and forecast, by Product
  • 7.2.4 North America Market size and forecast, by Application
    • 7.2.4.1 North America Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Type
    • 7.2.5.1.2 Market size and forecast, by Product
    • 7.2.5.1.3 Market size and forecast, by Application
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Type
    • 7.2.5.2.2 Market size and forecast, by Product
    • 7.2.5.2.3 Market size and forecast, by Application
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Type
    • 7.2.5.3.2 Market size and forecast, by Product
    • 7.2.5.3.3 Market size and forecast, by Application
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Type
  • 7.3.3 Europe Market size and forecast, by Product
  • 7.3.4 Europe Market size and forecast, by Application
    • 7.3.4.1 Europe Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Type
    • 7.3.5.1.2 Market size and forecast, by Product
    • 7.3.5.1.3 Market size and forecast, by Application
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Type
    • 7.3.5.2.2 Market size and forecast, by Product
    • 7.3.5.2.3 Market size and forecast, by Application
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Type
    • 7.3.5.3.2 Market size and forecast, by Product
    • 7.3.5.3.3 Market size and forecast, by Application
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Type
    • 7.3.5.4.2 Market size and forecast, by Product
    • 7.3.5.4.3 Market size and forecast, by Application
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Type
    • 7.3.5.5.2 Market size and forecast, by Product
    • 7.3.5.5.3 Market size and forecast, by Application
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Type
    • 7.3.5.6.2 Market size and forecast, by Product
    • 7.3.5.6.3 Market size and forecast, by Application
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Product
  • 7.4.4 Asia-Pacific Market size and forecast, by Application
    • 7.4.4.1 Asia-Pacific Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Type
    • 7.4.5.1.2 Market size and forecast, by Product
    • 7.4.5.1.3 Market size and forecast, by Application
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Type
    • 7.4.5.2.2 Market size and forecast, by Product
    • 7.4.5.2.3 Market size and forecast, by Application
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Market size and forecast, by Type
    • 7.4.5.3.2 Market size and forecast, by Product
    • 7.4.5.3.3 Market size and forecast, by Application
    • 7.4.5.4 India
    • 7.4.5.4.1 Market size and forecast, by Type
    • 7.4.5.4.2 Market size and forecast, by Product
    • 7.4.5.4.3 Market size and forecast, by Application
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Type
    • 7.4.5.5.2 Market size and forecast, by Product
    • 7.4.5.5.3 Market size and forecast, by Application
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Type
    • 7.4.5.6.2 Market size and forecast, by Product
    • 7.4.5.6.3 Market size and forecast, by Application
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Type
  • 7.5.3 LAMEA Market size and forecast, by Product
  • 7.5.4 LAMEA Market size and forecast, by Application
    • 7.5.4.1 LAMEA Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Type
    • 7.5.5.1.2 Market size and forecast, by Product
    • 7.5.5.1.3 Market size and forecast, by Application
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Type
    • 7.5.5.2.2 Market size and forecast, by Product
    • 7.5.5.2.3 Market size and forecast, by Application
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Type
    • 7.5.5.3.2 Market size and forecast, by Product
    • 7.5.5.3.3 Market size and forecast, by Application
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Type
    • 7.5.5.4.2 Market size and forecast, by Product
    • 7.5.5.4.3 Market size and forecast, by Application

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Agilent Technologies Inc
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 F Hoffman La Roche
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Merck Kgaa
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Bio Rad Laboratories
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Thermofischer Scientific Inc
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 Qiagen
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Perkin Elmer
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Charles River Laboratories International, Inc.
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Siemens Healthineers
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Eurofins Scientific, Inc.
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments